Abstract
背景与目的核糖核苷酸还原酶M1（ribonucleotide reductase M1, RRM1）的表达水平与肿瘤细胞对吉西他滨耐药密切相关。本研究旨在探讨晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）中RRM1蛋白的表达水平与吉西他滨联合顺铂（GP方案）化疗疗效的关系。方法应用免疫组织化学染色法检测75例晚期NSCLC组织中的RRM1蛋白表达，75例患者均接受GP化疗方案，回顾调查患者的一般特征、治疗反应、疗效评价及生存时间。组间差异采用卡方检验，采用Kaplan-Meier法进行生存分析。结果RRM1蛋白表达阳性率为38.7%，与患者的性别、年龄、吸烟状态、临床分期及组织病理学类型无明显相关性（P > 0.05）；RRM1蛋白高表达组的化疗有效率（31.1%）低于低表达组（41.3%），有统计学意义（P=0.005）；RRM1高表达组的1年生存率（27.6%）低于低表达组（58.7%），有统计学意义（P=0.009）；RRM1蛋白高表达组的中位生存期（10.70个月）低于低表达组（13.30个月），但无统计学差异（P=0.245）；RRM1蛋白高表达组的疾病进展时间（3.10个月）低于低表达组（5.11个月），差异有统计学意义（P=0.042）。结论晚期NSCLC患者组织中RRM1蛋白的表达水平与GP方案化疗的疗效及预后密切相关。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
